Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) has expanded its medical cannabis portfolio in Australia with the introduction of new product formats and formulations. The launch includes the company’s first pastilles and all-in-one vapes in the market.

The expansion targets established international markets as part of the company’s global medical strategy. It introduces products across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed, and Twd. brands.

New Product Formats

Canopy Growth introduced two distinct new formats for the Australian market:

• Pastilles: The company’s first pastille format in Australia, featuring Tweed Red 10, Tweed Blue 10:10, Spectrum Triple Balance 10:10:10, and Spectrum Dawn 1:10:5.
• All-in-one vapes: The company’s first AIO vape format in Australia, including 7 ACRES Fondant Live Resin AIO Vape 1 mL (Indica) and Spectrum Therapeutics Reserve Berea Live Resin AIO Vape 1 mL (Sativa).

Expanded Formulations

The company also broadened its existing oil and softgel ranges with new formulations:

• Oils: Canopy Growth’s first Australian oils to include CBG and CBN, specifically Spectrum Flow and Spectrum Sunset.
• Softgels: An expansion beyond isolate-based formulations, adding Spectrum White 50 and Spectrum Black 10.

Additionally, two new SKUs were added under the Twd. value range for flower products.

Strategic Context

Luc Mongeau, Chief Executive Officer of Canopy Growth, stated that expanding product offerings in established markets like Australia is central to the company’s international medical strategy. He noted that these new formats reflect the strength of the global supply chain and the ability to evolve the existing portfolio.

Andrew Bevan, President of Medical at Canopy Growth, highlighted that prescribers and patients in Australia are seeking more choice in format and formulation. He indicated that the new pastille and oil offerings reflect formulation work shaped by insights from the company’s Canadian clinic and provider network.

What the Numbers Show

The product launch signals a shift toward diversified delivery mechanisms in a mature market. By introducing pastilles and all-in-one vapes alongside traditional oils and softgels, Canopy Growth is addressing specific clinician requests for tailored treatment approaches rather than relying solely on volume growth in existing categories.

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) has secured renewed European Union Good Manufacturing Practice (EU GMP) certification for its Kincardine, Ontario cultivation facility. The certification was issued by the Regierungspräsidium Tübingen – Leitstelle Arzneimittelüberwachung Baden-Württemberg, validating the facility’s compliance with strict European regulatory standards for pharmaceutical-grade cannabis production.

The renewed status is critical for Canopy Growth’s supply chain integrity, allowing it to continue exporting Canadian-grown cannabis flower to medical markets across Europe. Kincardine serves as the anchor asset in the company’s end-to-end EU GMP supply chain, linking cultivation in Canada with distribution capabilities through its second EU GMP facility in Sankt Leon-Rot, Germany.

Operational Impact and Revenue Context

The certification renewal supports Canopy Growth’s expanding presence in the European market. Luc Mongeau, Chief Executive Officer of Canopy Growth, stated that the renewal reflects the quality and consistency of operations at Kincardine. He noted that the company is broadening its flower portfolio, including through the introduction of MTL Cannabis genetics and additional strains, to meet evolving patient needs.

Financially, the company reported momentum in Europe during the recent quarter. International cannabis net revenue increased 10% year-over-year in the first quarter of fiscal 2027. This growth underscores the commercial relevance of maintaining uninterrupted EU GMP-compliant supply from Kincardine.

What the Numbers Show

The correlation between the renewed certification and the 10% year-over-year rise in international cannabis net revenue highlights the dependency of Canopy Growth’s European expansion on regulatory continuity. Without the EU GMP status at Kincardine, the company would face significant barriers to supplying the region, potentially stalling the revenue growth observed in Q1 FY27. The data suggests that operational excellence in cultivation directly supports top-line performance in key international markets.